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Abstract
Introduction: Human APOBEC3G/F (hA3G/F) restricts retroviral replication through G-to-A hypermutations, which can generate
drug-resistant progenies in vitro. The clinical relevance is still inconclusive. To bridge this gap, we aim to study the role of these
hypermutations in evolution of drug resistance; we characterised hA3G/F-mediated hypermutations in the RT region of the pol
gene of patients with or without antiretroviral therapy (ART).
Methods: In 88 HIV-1-positive individuals, drug resistance genotyping was carried out in plasma virus and provirus by population
sequencing. Hypermutations were determined by three different approaches using Hypermut 2.0 software, cluster analysis and
APOBEC3G-mediated defectives indices. Clinical and demographic characteristics of these individuals were studied in relation to
these hypermutations.
Results: hA3G/F-mediated hypermutated sequences in proviral DNA, but not in plasma virus, were identified in 11.4% (10/88)
subjects. Proviral hypermutations were observed more frequently in patients with ART failure than in ART-naı ¨ve individuals
(p0.03). In therapy failure patients, proviral hypermutation were associated with greater intra-compartmental genetic
diversity (pB0.001). In therapy-naı ¨ve individuals, hypermutated proviral DNA with M184I and M230I mutations due to the
editing of hA3G, had stop codons in the open reading frames and the same mutations were absent in the plasma virus. Only a
limited concordance was found between the drug resistance mutations in plasma RNA and proviral DNA.
Conclusions: hA3G lethal hypermutation was significantly associated with ART failure in Indian HIV-1 subtype C patients.
It is unlikely that viral variants, which exhibit hypermutated sequences and M184I and/or M230I, will mature and expand in vivo.
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Introduction
The human apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like 3G (APOBEC3G or hA3G) belongs to a family
of at least 10 other proteins including hA3D, hA3F, hA3H
which acts as a potent host restriction factor of retroviral
replication through cytidine deaminase activity [1,2]. HIV-1
accessory protein vif interacts with hA3G and protects the
virus from its anti-viral activity [35]. In the presence of
defective vif, hA3G/F/D/H induces extensive dC-to-dU muta-
tions in the minus strand of the single stranded DNA [6],
consequently, dG-to-dA mutations in the plus strand of the
cDNA [3,7]. Generally, hA3G restricts viral replication through
lethal hypermutations by introducing stop codons into the
open reading frame (ORFs) of the retroviral gene mainly in
the tryptophan residue (TGG-to-TGA/TAA/TAG). However,
sub-lethal hypermutations have been suggested to contri-
bute to the HIV-1 genetic diversity [8] and the low level of
G-to-A mutation allows for greater genetic variations affect-
ing HIV-1 evolution [9].
Cytidine deamination in the proviral sequences can
generate drug-resistant progenies in vitro [10], though the
in vivo consequences of hA3G/F are not well understood.
Computer prediction of pol sequences has identified poten-
tial target sites for hA3G/F, but the role of hA3G in HIV-1 drug
resistance in vivo is unknown and considered to be low [9].
Also, most of the previous in vivo studies used HIV-1 genes
gag, env, vpu, and vif to identify hA3G induced hypermuta-
tions in proviral sequences [1113]. Only a few studies have
analysed the HIV-1 pol gene, which is a major target in
antiretroviral therapy (ART) [1416].
To bridge the gap between the in vitro observations and
the limited knowledge about the in vivo consequences,
we aimed to characterise the nature of hA3G/F-mediated
hypermutations in the RT region of the pol gene in a
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1population of Indian HIV-1-positive patients, and its correla-
tion with clinical and demographic parameters as well as with
drug resistance.
Methods
Patient populations
Blood samples were collected in EDTA tubes (BD, USA) from
102 HIV-1-positive individuals who were participants of on-
going studies in southern India between November 2009
and October 2011. Among the 102 patients, both RNA virus
and provirus were amplified in 86.2% (88/102), only RNA
virus in 5.9% (6/102) and only provirus in 7.8% (8/102). Only
paired sequences from both RNA virus and provirus (n88)
were included in the study. Among these patients, 56 were
ART naive and 32 were ART experienced at inclusion in
the study (Table 1). In the treatment-experienced patients,
the CD4T-cell values were B250 cells/ml when ART was
initiated, according to the Indian guidelines. The experienced
patients were on first-line therapy with two nucleoside RT
inhibitors (zidovudine or stavudine with lamivudine) and one
non-nucleoside RT inhibitor (nevirapine or efavirenz). Routine
CD4T-cells were measured with FACSCalibur system (BD,
USA). Viral load was measured every sixth month by Abbott
m2000rt system (Abbott Molecular Diagnostics, US). In the
treated patients, peripheral blood samples for this study
were obtained at the first virological rebound (median
duration 29 months; IQR: 1244 months).
PCR, proviral sequencing and subtyping
Plasma HIV-1 RNA and proviral DNA from whole blood were
extracted, amplified and sequenced, using an in-house
genotyping assay as described previously [17,18]. In brief,
a partial RT (17235 aa) region of the pol gene was amplified
from cDNA and proviral DNA, respectively, by conventional
nested PCR.The purified nested PCR products were subjected
to bidirectional population sequencing. Sequences were sub-
mitted to GeneBank with the following accession numbers:
KC307783KC307958.
HIV-1 subtyping was carried out using maximum likelihood
phylogenetic analysis with best-fitted model for the dataset
in MEGA 5.0 software [19]. Recombination was identified by
the RIP 3.0 program available in Los Alamos Database (www.
hiv.lanl.gov).
Estimation of G-to-A substitutions
To estimate G-to-A substitutions, proviral DNA sequences
were aligned against the consensus Indian subtype C
sequence [17]. The hA3G/F-mediated GG-to-AG and GA-
to-AA scores, respectively, for each sequence were calculated
[11]. The consolidated hA3G/F-mediated G-to-A hypermuta-
tion score was calculated as: [(Number of GG-to-AG or GA-
to-AA substitutions/number of GG or GA in Indian consensus
sequence)/(total number of mutations/sequence length)].
G-to-A preferences were calculated as described [11].
Identification of hypermutated sequences
Hypermut software was used to determine hA3G/F-mediated
hypermutated sequences [20]. Further cluster analysis of
preference for G-to-A substitutions relative to consolidated
hA3G/F score and sequence analysis of 21 hA3G and 20 hA3F
target sites in the 17235 aa of the RT region identified
by APOBEC3G-mediated defectives (A3GD) indices [21] were
also used. Hypermutations were labelled into a dichotomous
Table 1. Clinical and demographic data of all study subjects (n88) with hypermutated (n10) or non hypermutated (n78)
proviral sequences
Parameter All patients (n88) Hypermutated (n10) Non-hypermutated (n78) p*
Age
Years median (IQR) 36 (3041) 33 (2937) 37 (3042) 0.11**
Sex male, No (%) 56 (63.6%) 7 (70%) 49 (62.8%) 0.74***
Route of transmission
Heterosexual 69 (78.4%) 7 (70%) 62 (79.5%) 0.66***
Perinatal 15 (17%) 2 (20%) 13 (16.7%)
Other/unknown 4 (4.5%) 1 (10%) 3 (3.8%)
CD4 T-cells/mm
3
Median (IQR) 208 (117363) 262 (154485) 199 (98356) 0.14**
HIV RNA log10 copies/ml
Mean (SD) 5.03 (0.86) 4.79 (0.75) 5.05 (0.88) 0.25**
Treatment, No (%)
Yes 32 (36.3%) 7 (70%) 25 (32.1%)
No 56 (63.6%) 3 (30%) 53 (67.9%) 0.03***
HIV-1 subtype C (98.9%) A1C (1.1%) C (100%) C (98.7%) A1C (1.3%) 
CD4 T-cells and HIV RNA analysed at therapy failure in treatment experienced patients. The CD4 T-cells were B250 cells/ml, when ART was
initiated; all treated patients were given first-line therapy (zidovudine or stavudine with lamivudine and nevirapine or efavirenz).
*P values based on the comparison between patients with hypermutated versus non-hypermutated sequence; the percentage mentioned is the
percentage of each subsets; **MannWhitney U Test; ***Fisher’s exact test.
Statistical significance (pB0.05) is marked in bold letters.
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2variable if identified by one of the methods mentioned.
Mutations were designated as lethal if there was stop codon
in the ORFs.
Drug resistance mutations and nucleotide divergence
The World Health Organization (WHO) recommendations
for surveillance of drug resistance mutations updated in the
2009 (SDRM_2009) list were used to define the transmitted
drug resistance mutations in therapy-naı ¨ve patients [22].
Drug resistance mutations in therapy failure patients in the
RT region (17235 amino acids) listed in the December 2011
update from the International AIDS Society were considered
[23]. The genetic distance of each of the sequences to the
Indian consensus C sequence (intra-population divergence)
and the intra-compartmental genetic diversity were calcu-
lated in MEGA 5 software [19].
Statistical analysis
Descriptive statistics were used to describe the character-
istics of the patients. The demographic, clinical and viral
genetic differences between hypermutated and non-
hypermutated groups were evaluated by MannWhitney
U Test and Fisher’s exact test. Spearman rank co-relation
was used to find associations between different factors.
The statistical analysis was calculated in SPSS software
version 16.
Ethical approval
The study was approved by Institutional Ethical Review
Board, St. John’s Medical College Hospital, Bangalore, India
(IERB Study No. 153/2010). Written informed consent was
obtained from all the adult participants and the caregivers
of the children prior to recruitment, and a verbal assent was
obtained from children older than nine years.
Results
Subtyping
Subtype C was identified in 98.9% (87/88) of the patients
along with one A1C recombinant strain. Phylogenetic analysis
using the sequences from both compartments verified the
common origin of the strains in each individual.
Identification of hA3G-hypermutations
hA3G mediated hypermutated sequences in proviral DNA
were identified in 11.4% (10/88) of the patients (Figure 1).
However, the event of hypermutation was not detected in
the plasma viral RNA. Among the clinical and demographic
factors, only treatment failure was associated with hypermu-
tation as compared to naı ¨ve patients (Table 1) (p0.03;
Fisher’s exact test). Patients failing therapy had a 4.96-fold
(OR; 95% CI; 1.18, 20.75) higher risk of lethal hypermuta-
tions than therapy-naive patients. Among the six therapy-
experienced patients whose samples were available before
therapy, two had hypermutated proviral sequences at failure
but not when they were therapy-naı ¨ve.
Association of G-to-A substitutions to clinical and
demographic parameters in therapy-experienced patients
Among therapy-experienced patients, univariate analysis
revealed no significant association with respect to patients’
clinical-demographic parameters and the presence of hyper-
mutated or non-hypermutated sequences (Table 2). It is likely
that the patients had reached their set point for viral load
after failure and it did not differ between those with or
without hypermutated sequences. A difference between the
Figure 1. hA3G mediated hypermutations in proviral DNA.
The sequences were run in the HyperMut software with Indian consensus C sequences as a reference sequences. GG to AG mutations were
labelled in red, GA to AA in cyan, GC to AC in green, GT to AT in magenta.
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3hypermutated and non-hypermutated therapy-experienced
groups was observed in the hA3G-specific G-to-A score
(pB0.001) and the intra-compartmental genetic diversity
(pB0.001), but not in the hA3F-specific G-to-A score
(Table 2).
Correlation between hA3G mediated hypermutation and
viral heterogeneity
When all of the patients were analysed, the consolidated
hA3G specific G-to-A score was weakly associated with
proviral divergence (Spearman rho 0.24; p0.02),
but not with plasma viral divergence. This correlation
was found in the therapy-experienced patients only
(Spearman rho 0.57; p0.001), but not in the therapy-
naive individuals.
Mutations in computer derived hA3G/F motifs
Among the hypermutated proviral DNA sequences, substitu-
tions were observed in 31 aa residues, mainly in glycine
and tryptophan (Figure 2). None of these mutations have
been previously reported in HIV-1 subtype C, using Stanford
Database HIVseq program. The three hypermutated proviral
sequences from the therapy naive patients who had M184I
and M230I drug resistance mutations and mutation in drug
resistance position (M41I) also had stop codons in the RT
ORF particularly at the tryptophan residue, which is the
target site for hA3G.
Drug resistance mutations
Among the 56 treatment naı ¨ve patients, transmitted drug
resistance mutations (DRM) were observed in both compart-
ments of one patient giving the prevalence of transmitted
drug resistance as 1.8% (1/56). One patient had D67DN and
K70KE mutations in the proviral sequence. In one patient
with hypermutated sequence, M184I was observed in the
proviral sequence but not in plasma. Therefore, a high level
of concordance in DR Genotyping (94.6%, 53/56) was
observed in the therapy-naı ¨ve individuals.
DRM were found in 84.4% (27/32) of the patients failing
ART (Table 3). Exactly the same DRM in the RNA and DNA
sequences were observed in 43.8% (14/32) of patients. As
expected, among the NRTI and NNRTI mutations, M184I/V
(71.9%), T215Y/F (34.4%), K103N (34.3%), and Y181C (28.1%)
were the most prevalent in any of the compartments. This
discrepancy was not only because of the hA3G restriction.
Among the discordant sequence, only three (16.7%; 3/18)
had hA3G associated hypermutations in their proviral
sequences.
Important differences were found between the plasma
RNA and the proviral DNA compartments. M184Vand T215Y/
F were observed in plasma only in six and three patients,
respectively, while M41L and K65R were observed in one
patient each in provirus only. Additional NRTI mutations
were observed in 25% (8/32) of proviral and plasma viral
sequences, respectively. Additional NNRTI mutations were
found mainly in plasma (31.2%; 10/32) and to a lesser extent
in proviral DNA (12.5%; 4/32). In two proviral sequences only,
the E138K mutation was observed.
Discussion
In the present study, hA3G mediated lethal hypermutations
were identified in the clinically important pol gene of proviral
DNA from a minority (11.4%) of 88 Indian HIV-1 subtype
C-infected patients. The hypermutations occurred more
frequently in patients failing therapy than in therapy-naı ¨ve
patients. There was a correlation between their presence
Table 2. Clinical, laboratory and viral genetic factors of the patients with ART failure
Parameter Hypermutated (n7) Non-hypermutated (n25) p
Age
Years median (IQR) 35 (23.536.5) 38.5 (2945) 0.18*
Sex
Male (%) 5 (71.4%) 17 (71%) 0.98**
CD4 T-cell count/mm
3
Median (IQR) 278 (178638) 268 (172404) 0.54*
Viral load log10 copies/ml
Mean (SD) 4.36 (4.194.96) 4.27 (3.464.95) 0.44*
Duration of ART
Median (IQR) 12 (1045) 30 (1438) 0.51*
Consolidated scores mean (SD)
hA3G G-to-A 7.72 (4.20) 1.80 (0.94) B0.001*
hA3F G-to-A 2.70 (2.38) 1.36 (0.74) 0.21*
Viral divergence mean (SD)
Proviral DNA 0.09 (0.04) 0.04 (0.01) B0.001*
Plasma RNA 0.02 (0.01) 0.03 (0.01) 0.43*
Intra-compartmental genetic diversity
Median (IQR) 0.05 (0.040.07) 0.01 (0.0070.014) B0.001*
*MannWhitney U Test; **Fisher’s exact test.
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4and the proviral divergence, which is in line with the view
that hA3G contributes to viral evolution.
In vitro studies and computer predictions have suggested a
role of hA3G in the evolution of HIV drug resistance [9,10].
Thus, due to a suboptimal anti-APOBEC3G activity of HIV-1
Vif mutants, the HIV drug resistance mutations M184I [10,16]
and E138K [16] may be induced in vitro without any drug
exposure. Also, one study has reported the co-presence
of M184I and E138K in 24% of hypermutated sequences of
treated patients [16]. In contrast, co-evolution of M184I
and E138K was not found in our hypermutated sequences.
However, random polymorphisms of E138K/A were observed
in the proviral DNA of both therapy-naı ¨ve and experienced
patients.
In addition to these in vitro results, differences have been
reported on how often hA3G induced mutations can be
found in vivo. When analysing HIV clones, hypermutated
proviral DNA was detected in resting T-cells of all nine treated
patients who had undetectable viremia, suggesting that
the mutated viral genomes were able to integrate and
persist in these cells [14]. In contrast, a minority (9.4%) out
of 127 untreated subtype B infected mainly Caucasians
exhibited such mutations at population based sequencing
[13]. Furthermore, an even lower prevalence (4.8%) was
found in 601 proviral DNA sequences of treated patients
derived from a French database [16]. In our study, higher
hypermutated proviral DNA was found in patients failing
ART, but in naı ¨ve patients the incidence was very low.
Altogether, these data suggest that hA3G generated muta-
tions are common but are mostly restricted to a minor viral
population. However, it also seems possible that, in addition
to the different techniques used, either clonal analysis or
population based sequencing, the characteristics of patients
studied might influence the extent hypermutations are
found. Our data indicate that hypermutated proviral DNA
accumulates in patients with therapy failure. This is further
supported by the increase in intra-compartmental genetic
diversity in patients with hypermutated proviral DNA as
compared to those without. Also, in a re-analysis of earlier
published sequences from India [24], we observed hA3G
restriction in only two sequences of therapy-experienced
patients. A recent study on five patients with long term
successful treatment showed that these five patients har-
boured more in-frame stop codons in the proviral compart-
ment compared to the therapy-naı ¨ve patients [25], thus
the effective ART may lead to the accumulation of the
defective genomes in the reservoir [25].
No hypermutation in plasma HIV RNA was found. This is in
line with the finding that the viruses released into plasma at
low levels in nine patients on successful ART were devoid of
hypermutated sequences [14]. This data is further strength-
ened by the observation from the Swedish InfCare HIVcohort
in which only three hypermutated RT sequences have been
found after analyzing  2000 tested samples (unpublished
data). As the hypermutated sequences with DRM (M184I;
M230I) had stop codons in the ORFs and the absence of
these DRMs in the plasma viral RNA, it is unlikely that such
proviral variants will mature and expand in vivo.The presence
of an increased number of hypermutated sequences in the
therapy failure patients might be associated with decreased
fitness of the virus due to the DRMs [26] as these strains
might be superimposed by the more replication competent
viruses compared to the less fit DRMs containing viruses
after the treatment was initiated.
In addition to our analysis of hA3G mutations, we
compared the sequences with regard to DRM. Transmitted
drug resistance was uncommon which is concordant with
previous findings [17,27]. For the failing patients, the DRM
were expected [28,29]. However, we found a low level of
concordance between the DRM in plasma and proviral DNA
which is in line with the study of Chew et al. where DRM
were more common in plasma [4]. In contrast, a study from
Figure 2. Mutations in hA3G/F target motifs in HIV-1 subtype C patients.
Number of mutations in the hA3G/F target motifs identified by APOBEC3G-mediated defective (A3GD) indices [21] were presented. Blue bar
represents sequence from therapy-experienced patients and red bar represents therapy naive patients. ‘‘*’’ indicates stop codon. Clinically
important drug resistance mutations positions are marked with a box.
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5Honduras showed 88% concordance between both compart-
ments in heavily ART-treated patients [30].
The presence of drug resistance mutations like M184V,
T215Y, K103N, and Y181C in plasma virus but not in the
provirus in our study indicates that routine HIV RNA
monitoring every six months and subsequent plasma viral
genotyping at failure identifies the most recent viral popula-
tions circulating, although different sources of the two viral
populations cannot be excluded. Therefore, in such a setting,
testing of proviral DNA could possibly underestimate the
true burden of recently developed resistant virus. However,
the presence of key mutations in the proviral DNA which
was not present in plasma is of importance for the selection
of future ART regimen. World Health Organisation recom-
mends the use of dried blood spot for transmitted drug
resistance surveillance but not in patients undergoing
therapy [31]. High concordance in the DR Genotyping in
both the compartment in therapy-naı ¨ve patients corrobo-
rates the idea. It may solve the logistics challenges in
countries where most of the part the cold chain transport
is not available. Thus, although routine drug resistance
testing is frequently not affordable in resource-poor settings,
further studies are recommendable to evaluate which
compartment to analyse, especially in patients on therapy.
Our study has some inadvertent caveats. First, the
analysis is based on population sequencing and therefore
Table 3. Drug resistance mutations in plasma RNA and proviral DNA in therapy-experienced patients
Plasma virus Provirus
NRTI mutations NNRTI mutations NRTI mutations NNRTI mutations hA3G
1 M41L, D67N, K70R, M184V, T215Y,
K219E
Y188L M41L, D67N, K70R, V75I, M184V,T215Y,
K219E
Y188L, M230I Yes
2 D67N, T215Y, K219E Y188L D67N, K70KR, M184V, T215Y, K219E L100I, Y188L
3 M184V Y181C M184V Y181C
4 M184V, T215Y, K219Q K103N, M230L M184V, T215Y, K219Q K103N, M230L
5 None V106A None V106A
6 M41L, D67N, K70R, M184V, T215Y A98G, K101E, G190A M41L, D67N, K70R, M184V, T215Y A98G, K101E, G190A
7 D67N, K70R, M184V, K219E V106M, F227L D67N, K70R, M184V, K219E V106M, F227L
8 None None None None Yes
9 K70R, M184V, K219E K103N, Y181C K65KR, K70R, M184V, K219E K103N, Y181C
10 M184V, T215Y K101E, V108I, Y181C None None
11 None None None None
12 M41L, L74V, M184V, L210W, T215Y V108I, Y181C M41L, L74V, M184V V108I, E138K, Y181C Yes
13 M184V, T215Y A98G, K101E, G190A None A98G, G190A
14 D67N, K70R, M184V, K219E K103N, G190A M184V None
15 M41L, M184V, T215F A98G, K103N M41L, M184V, T215F A98G, K103N
16 M184V Y181C None None
17 M184V Y181C M184V Y181C
18 M184V K101E, V106M, G190A M41L, D67G, M184V K101E, V106M, G190A
19 M184V K103N M184V K103N, M230I Yes
20 None None None None Yes
21 None K103N None E138K
22 None V106M None V106M
23 None None M184I M230I Yes
24 M184V K103N M184V K103N
25 M184V K103N None None
26 M184V Y181C None None Yes
27 M184V K103N, Y181C None None
28 M41L, M184V, T215Y K103N, V108I, Y181C,
G190A
M41L, L74V, M184V, T215Y K103N, V108I, Y181C,
G190A
29 None None None None
30 None V106M D67DN G190AG
31 None None None None
32 M41L, D67N, M184V, L210W A98G, K101E, V106IM,
G190A
M41L, D67N, M184V, L210W, T215Y A98G, K101E, G190S
Discordant mutations are marked bold.
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6does not detect any hypermutations in the minor quasi-
species. Second, the number of therapy failure patients is
low compared to the treatment naı ¨ve individuals. This is due
to a low number of treatment failures in our settings
because of high ( 95%) adherence. We have thus observed
only 2.8% (9/323) of viral treatment failure with a median
duration of four years of therapy who had initially
suppressed viremia following the initiation of the therapy
[32]. Third, we do not know to which extent the mutations
were present before initiation of ART since the analysed
longitudinal samples from six patients only before and after
therapy. However, even in this small sample size, hypermu-
tation developed during therapy failure in two subjects.
Conclusions
In conclusion, our study showed for the first time that hA3G
lethal-hypermutation was associated with the use of
treatment in Indian patients who failed ART. Though DRM
were present in the hypermutated proviral compartment,
all strains had a stop codon in its ORF.Therefore, it is unlikely
that such viral variants will mature and expand in vivo which
is supported by the absence of those mutations in plasma
viral populations. However, further studies are required to
validate the idea with appropriate in vitro cell culture models
and with analysis of a large number of patients to gain the
mechanistic view of the role of hA3G in the evolution of
drug resistance and its clinical consequences. The evidence
from this study also suggests the possible use of proviral
drug resistance genotyping as an alternate to plasma viral
genotyping for surveillance of transmitted drug resistance
in resource-limited settings, specifically from the rural and
remote part of the country where the logistics challenges
remain.
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